Yes, fatty liver is officially classified as a liver disease. It is, in fact, the most common chronic liver disease in the world, affecting an estimated 1.3 billion people globally as of 2023. The condition was recently renamed to reflect its seriousness: what doctors used to call nonalcoholic fatty liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease, or MASLD.
The name change wasn’t cosmetic. It signals a shift in how the medical community understands and categorizes the condition, placing it firmly within a spectrum of progressive liver disease that, in some people, can advance to scarring and liver failure.
Why the Name Changed in 2023
Major hepatology organizations adopted the new terminology in 2023, replacing the old “nonalcoholic fatty liver disease” label. The original name defined the condition by what it wasn’t (not caused by alcohol) rather than what it was. The new name, MASLD, directly ties the disease to its actual driver: metabolic dysfunction.
Under the updated system, “steatotic liver disease” serves as the umbrella term for any condition involving excess fat in the liver, regardless of cause. MASLD specifically applies when fat buildup occurs alongside at least one of five cardiometabolic risk factors, such as obesity, high blood sugar, or abnormal cholesterol. When the disease progresses to include active inflammation and liver cell damage, it’s now called MASH (metabolic dysfunction-associated steatohepatitis), replacing the older term NASH.
What Happens Inside the Liver
A healthy liver contains some fat. The disease begins when fat accumulates in more than 5% of liver cells. At that point, the organ is working under a burden it wasn’t designed to carry.
The underlying problem in most cases is insulin resistance. Normally, insulin helps regulate both blood sugar and fat metabolism. In people with MASLD, insulin loses its ability to keep glucose production in check and to prevent fat from being released into the bloodstream, but it still stimulates the liver to produce new fat. The result is a one-way accumulation of triglycerides inside liver cells. The fat itself may not directly poison those cells, but the byproducts of excess fat metabolism appear to trigger inflammation and injury over time.
The Stages of Progression
Fatty liver disease exists on a spectrum, and not everyone progresses through every stage. The earliest form involves fat accumulation alone, with little or no inflammation. Many people stay at this stage for years or even decades without significant liver damage.
When the liver becomes inflamed and individual cells begin to swell and die, the condition has advanced to MASH. This is where real damage starts. The liver responds to repeated injury by laying down scar tissue, a process called fibrosis. Doctors grade fibrosis on a scale from F0 (no scarring) through F4 (cirrhosis, where scar tissue has extensively replaced healthy liver tissue). Fibrosis stage is the single most important factor in determining long-term outcomes.
Roughly 10 to 25% of people with MASH develop advanced fibrosis or cirrhosis. A small number go on to develop liver cancer. But those numbers also mean the majority of people with fatty liver disease never reach the most severe stages.
The Bigger Threat Isn’t Always the Liver
Here’s something that surprises many people: most patients with fatty liver disease don’t die from liver-related complications. They die from cardiovascular events like heart attacks and strokes. A large meta-analysis found that people with fatty liver disease face roughly 45% higher risk of fatal and non-fatal cardiovascular events compared to those without the condition.
This doesn’t mean liver fat directly clogs your arteries. The research suggests that the same metabolic problems driving fat into your liver, particularly abnormal cholesterol and blood sugar levels, are also damaging your blood vessels. The liver disease and the heart risk share common roots. That’s one reason the renaming matters: calling it “metabolic dysfunction-associated” reminds both patients and doctors to look beyond the liver.
How It’s Detected
Fatty liver disease rarely causes symptoms in its early stages. Most people find out they have it incidentally, through blood tests showing elevated liver enzymes or an imaging scan done for another reason. Ultrasound can reveal fat in the liver, but it can’t precisely measure how much scarring has occurred.
To assess fibrosis without an invasive procedure, doctors use scoring tools that combine routine blood test results (and sometimes your age) into a risk estimate. The most common is the FIB-4 score. A specialized ultrasound called transient elastography, often known by the brand name FibroScan, measures liver stiffness, which correlates directly with the amount of scar tissue present. Liver biopsy remains the gold standard for confirming exactly how much damage exists, but it’s typically reserved for cases where the diagnosis is uncertain or the disease appears advanced.
Reversibility and Weight Loss Targets
The most encouraging aspect of fatty liver disease is that it can be reversed, particularly in the earlier stages. Weight loss is the most effective intervention, and the targets are specific. Losing 3 to 5% of your body weight is typically enough for fat to begin clearing from liver cells. For someone who weighs 200 pounds, that’s 6 to 10 pounds. Reaching a 10% weight loss can improve not just the fat accumulation but also the inflammation and scarring that characterize more advanced disease.
The method of weight loss matters less than the result. Dietary changes, increased physical activity, and in some cases medication or bariatric surgery all reduce liver fat effectively. No specific diet has proven superior, though reducing sugar and refined carbohydrates addresses the insulin resistance at the core of the problem. Exercise helps even when it doesn’t produce significant weight loss, likely because it improves insulin sensitivity on its own.
For people who have already progressed to cirrhosis, the damage is largely irreversible, though further progression can still be slowed. This is why catching the disease early, while it remains in the fatty or mildly inflamed stage, makes such a difference in long-term outcomes.